AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method of treating an ocular allergy in a subject consisting of administering to the eye surface of the subject, a pharmaceutical composition consisting of an effective concentration of ketotifen and an effective concentration of pheniramine in a pharmaceutically acceptable carrier.

2. (Original) The method of claim 1 wherein the effective concentration of ketotifen is between 0.04 % and 0.06%.

3. (Original) The method of claim 1 wherein the effective concentration of pheniramine is between 0.4% and 0.6%.

4. (Currently Amended) The method of claim 1 wherein the pharmaceutical composition further ~~consisting~~ consists of artificial tears.

5. (Original) A pharmaceutical composition consisting of an effective concentration of ketotifen and an effective concentration of pheniramine in a pharmaceutically acceptable carrier.

6. (Original) The pharmaceutical composition of claim 5 wherein the effective concentration of ketotifen is between 0.04% and 0.06%.

7. (Original) The pharmaceutical composition of claim 5 wherein an effective concentration of pheniramine is between 0.4% and 0.6%.

8. (Original) The pharmaceutical composition of claim 5 further consisting of artificial tears.

9. (Currently Amended) A method of treating an ocular allergy in a subject consisting of administering to the eye surface of the subject, a pharmaceutical composition consisting of an effective concentration of azelastine and an effective concentration of antazoline in a pharmaceutically acceptable carrier.

10. (Original) The method of claim 9 wherein the effective concentration of azelastine is between 0.04% and 0.06%.

11. (Original) The method of claim 9 wherein the effective concentration of antazoline is between 0.4% and 0.6%.

12. (Currently Amended) The method of claim 9 wherein the pharmaceutical composition further ~~consisting~~ consists of artificial tears.

13. (Original) A pharmaceutical composition consisting of an effective concentration of azelastine and an effective concentration of antazoline in a pharmaceutically acceptable carrier.

14. (Original) The pharmaceutical composition of claim 13 wherein an effective concentration of azelastine is between 0.04% and 0.06%.

15. (Original) The pharmaceutical composition of claim 13 wherein an effective concentration of antazoline is between 0.4% and 0.6%.

16. (Original) The pharmaceutical composition of claim 13 further consisting of artificial tears.

17. (Currently Amended) A pharmaceutical composition ~~comprising~~ consisting of an effective concentration of azelastine and an effective concentration of a short-acting anti-histamine agent.

18. (Currently Amended) A pharmaceutical composition ~~comprising~~ consisting of an effective concentration of ketotifen and an effective concentration of a short-acting anti-histamine agent.

19. (Currently Amended) A pharmaceutical composition ~~comprising~~ consisting of an effective concentration of pheniramine and an effective concentration of a long-acting anti-histamine agent.

20. (Currently Amended) A pharmaceutical composition ~~comprising~~ consisting of an effective concentration of antazoline and an effective concentration of a long-acting anti-histamine agent.

21. (New) The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier comprises a member selected from the group consisting of a tonicity enhancing agent, a solubilizer, a demulcent, a preservative, and a buffer.

22. (New) The pharmaceutical composition of claim 5, wherein the pharmaceutically acceptable carrier comprises a member selected from the group consisting of a tonicity enhancing agent, a solubilizer, a demulcent, a preservative, and a buffer.

23. (New) The pharmaceutical composition of claim 9, wherein the pharmaceutically acceptable carrier comprises a member selected from the group consisting of a tonicity enhancing agent, a solubilizer, a demulcent, a preservative, and a buffer.

24. (New) A pharmaceutical composition of claim 13, wherein the pharmaceutically acceptable carrier comprises a member selected from the group consisting of a tonicity enhancing agent, a solubilizer, a demulcent, a preservative, and a buffer.